97021 Jadoon KA, Ratcliffe SH, Barrett DA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016 Oct;39(10):1777-86. View abstract.
Bolognini D, Costa B, Maione S, et al. The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol. 2010;160(3):677-87. View abstract.
Cascio MG, Zamberletti E, Marini P, Parolaro D, Pertwee RG. The phytocannabinoid, ??-tetrahydrocannabivarin, can act through 5-HT1A receptors to produce antipsychotic effects. Br J Pharmacol. 2015;172(5):1305-18. View abstract.
Deiana S, Watanabe A, Yamasaki Y, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), ??-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl). 2012;219(3):859-73. View abstract.
Englund A, Atakan Z, Kralj A, Tunstall N, Murray R, Morrison P. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. J Psychopharmacol. 2016;30(2):140-51. View abstract.
Espadas I, Keifman E, Palomo-Garo C, et al. Beneficial effects of the phytocannabinoid delta(9)-THCV in L-DOPA-induced dyskinesia in Parkinson's disease. Neurobiol Dis. 2020;141:104892. View abstract.
Hill AJ, Weston SE, Jones NA, et al. ??-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia. 2010;51(8):1522-32. View abstract.
Pagano E, Montanaro V, Di Girolamo A, et al. Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol. Nat Prod Commun. 2015;10(6):1009-12. View abstract.
Raïch I, Rivas-Santisteban R, Lillo A, et al. Similarities and differences upon binding of naturally occurring ?(9)-tetrahydrocannabinol-derivatives to cannabinoid CB(1) and CB(2) receptors. Pharmacol Res 2021;174:105970. View abstract.
Rock EM, Sticht MA, Duncan M, Stott C, Parker LA. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and ?(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol. 2013;170(3):671-8. View abstract.
Romano B, Pagano E, Orlando P, et al. Pure ?9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in ?9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. Pharmacol Res. 2016;113(Pt A):199-208. View abstract.
Rzepa E, Tudge L, McCabe C. The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers. Int J Neuropsychopharmacol. 2015;19(2). pii: pyv092. View abstract.
Straiker A, Wilson S, Corey W, et al. An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models. Molecules 2021;26(17):5352. View abstract.
Tudge L, Williams C, Cowen PJ, McCabe C. Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. Int J Neuropsychopharmacol. 2014;18(6). pii: pyu094. View abstract.
Wargent ET, Zaibi MS, Silvestri C, et al. The cannabinoid ?(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes. 2013;3:e68. View abstract.
Xi ZX, Muldoon P, Wang XF, et al. ?8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. Br J Pharmacol. 2019. View abstract.
Zagzoog A, Mohamed KA, Kim HJJ, et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep 2020;10(1):20405. View abstract.